San Diego, Washington DC, New York ! What a fantastic holiday I hear you say….NOT.
Despite a day at the Zoo in San Diego (see very cute Panda ) it was all go in the US for the PRI. First stop San Diego after 20 hours of planes and airports with visits to several potential new members in La Jolla followed by the Global Engage – Microbiome R&D and Business Collaboration forum with over 400 attendees gathered together under the San Diego sunshine!
The sunshine played “second fiddle” however to lots of interesting presentations from the world of the Microbiome from the likes of Jack Gilbert, Rob Knight, Sarkis Masmanian and some really interesting commercial input from Ken Blount of Rebiotix and Ashton Harper of Protexin, amongst others!
A quick overnight flight across the US and the next morning I was in Washington DC, the nation’s capital, where it was, as you can see, raining; goodbye California sunshine! The Microbiome World Congress was run in conjunction with a Precision Medicine summit and was a more low-key affair than San Diego. However this gave me the opportunity to understand the FDA’s approach to interacting with LBP drug developers, as well as to meet with several potential new members of the PRI.
So far we have come back from the US with 4 new members for the PRI and hopefully several more in the coming weeks.
- Matrisys Bioscience, founded in 2015, the company is developing rational microbiome therapies based on Dr. Richard L. Gallo’s basic and clinical research for the top 5 dermatology and skin care conditions – Acne, Atopic Dermatitis (AD), Rosacea, Psoriasis, and skin infections, which have a huge impact on patients’ quality of life. More than 230 million patients suffer from these 5 skin diseases. We’d like to welcome Mark Wilson and the team to the PRI.
- Microbiome Insights, situated in the heart of the University of British Columbia (UBC) campus, was born from both the Life Science Institute and the Personalized Medicine Initiative. The scientific backbone of the company is formed by UBC professors Dr. Brett Finlay and Dr. Bill Mohn, and CEO Malcolm Kendall. Understanding the microbiome is one of the fastest growing areas of science, and a critical part of investigating how microbes function in and interact with their environments. Our team of experts and testing methods combine to provide end-to-end service with comprehensive bioinformatics for clients interested in including microbiome analysis into their studies.
- Quay Pharma – is a UK based CDMO with an exceptional depth of knowledge and experience that enables them to design novel and effective drug delivery systems built on a fundamental scientific and technical understanding of their clients’ requirements. They offer every client a bespoke approach matched precisely to their needs and circumstances.
- Siolta Therapeutics, born out of the Lynch Laboratory at UCSF, they harness information from human microbiome studies to design next-generation microbial therapeutics that re-engineer the human microbiome to prevent or reduce inflammatory processes. Initial drug development is around asthma in children with many other therapeutics in the pipeline.
For those of you who don’t know us, the PRI is a European non-profit clearing the regulatory pathways forward for Microbiotic Medicinal Products, operating the only network in the Human Microbiome Supply Chain and promoting scientific exchange among our members. We also host a PharmabioticsGlobal conference in Paris every year in March!